Exciting Progress for Clearmind Medicine in Clinical Trials
Clearmind Medicine Inc. (NASDAQ: CMND), a pioneer in the field of psychedelic-derived therapeutics, has achieved a significant milestone by receiving final approval for expanding its FDA-regulated Phase 1/2a clinical trial. This trial will assess the effectiveness of CMND-100, a novel drug candidate, in treating Alcohol Use Disorder (AUD). The approval comes from Hadassah Medical Center, a prestigious clinical research facility.
Innovation at Hadassah Medical Center
Hadassah Medical Center will join this essential clinical study, contributing to its robust roster of participating institutions, which includes prestigious names such as Yale School of Medicine and Johns Hopkins University School of Medicine. The study will be conducted under the guidance of Prof. Joseph Caraco, a leading figure in clinical pharmacology, who is set to lead the research at Hadassah.
Addressing Alcohol Use Disorder on a Global Scale
According to the World Health Organization, AUD is a profound public health challenge, representing 4.7% of all global deaths. Clearmind's clinical trial is designed to be both multinational and multi-center, addressing AUD through comprehensive evaluation of safety, tolerability, and the pharmacokinetic profile of CMND-100. This initiative aims not only to uncover its preliminary efficacy in reducing alcohol cravings but also to pave the way for groundbreaking treatments for individuals affected by AUD.
About Clearmind Medicine Inc.
Clearmind positions itself as a clinical-stage biotech leader, committed to finding innovative psychedelic-derived solutions to address widespread health issues. The company’s vision revolves around developing these compounds into regulated treatments to aid individuals suffering from conditions like AUD. Their product pipeline reflects a commitment to research and commercial viability, embracing the potential of psychedelic compounds.
Expanding Intellectual Property Portfolio
The company currently boasts an impressive intellectual property portfolio, encompassing nineteen patent families and 31 granted patents. This robust framework allows Clearmind to be proactive in seeking additional patents and acquiring relevant intellectual property to strengthen its position in the biotech landscape.
Contact Information for Interested Parties
For more information about Clearmind's work and inquiries, please contact their Investor Relations team. You can reach them by phone at (604) 260-1566 or by emailing CMND@crescendo-ir.com. Additionally, general inquiries can be directed to Info@Clearmindmedicine.com.
Frequently Asked Questions
What is the significance of this clinical trial for Clearmind Medicine?
This clinical trial is a crucial step that aims to evaluate the efficacy of CMND-100 in treating Alcohol Use Disorder, potentially leading to groundbreaking treatment solutions.
Who are the institutions involved in the clinical trial?
The trial involves prestigious institutions such as Hadassah Medical Center, Yale School of Medicine, and Johns Hopkins University School of Medicine.
What are the main goals of the Phase 1/2a clinical trial?
The primary goals are to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, as well as its effectiveness in reducing alcohol cravings in patients.
How does Clearmind's drug candidate differ from others?
CMND-100 is based on a proprietary MEAI compound and is designed to provide a novel therapeutic approach to treating Alcohol Use Disorder.
Where can I find more information about Clearmind Medicine?
For additional details, you can visit their official website at www.clearmindmedicine.com.
